BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting…

Read More

What’s in a Name? From Today’s Medicare to Medicare for All

In this JAMA Health Forum post, KFF’s Larry Levitt explains how proposals to create Medicare-for-All promise more generous benefits than the existing Medicare program, with no premiums or cost-sharing, but could end up looking more like Medicare if it became the subject of a serious national debate about the tradeoffs involved to implement it.

Read More

Data Center Health Worries Animate Midterm Campaigns

PAGE, Ariz. — Doug Herrera still lives in the house his father built, though his dad died some time ago from cancer. Herrera wonders if that illness could have been linked to pollutants from nearby uranium mining. Now, he worries that a possible new neighbor — a proposed $10 billion mega data center — could…

Read More